Boston Scientific Begins Marketing Remote Catheter System in Europe Through Exclusive Agreement With Catheter RoboticsBy Boston Scientific Corporation, PRNE
Monday, November 14, 2011
PARIS, November 15, 2011 -
CRI’s Amigo™ system allows remote control of Boston Scientific’s leading cardiac ablation catheters
Boston Scientific Corporation (NYSE: BSX) is beginning to market the CRI Amigo™ system, a remote-controlled catheter system, and related accessories in select European countries through an exclusive agreement with Catheter Robotics, Inc. (CRI). The CRI Amigo™ system, compatible with certain Boston Scientific and other commercially available catheters, lets physicians remotely maneuver diagnostic and ablation catheters designed to treat common cardiac arrhythmias during electrophysiology procedures. Boston Scientific plans to market the Amigo system in Austria, Belgium, France, Germany, Luxembourg, The Netherlands, Portugal, Spain and Switzerland.
“To perform successful ablation procedures, electrophysiologists require precise control over catheter tip placement,” said Jean Paul Albenque, M.D., Clinique Pasteur, Toulouse, France. ”The Amigo Remote Catheter System, used in combination with the predictable steering and stability of Boston Scientific’s leading RF ablation catheters, offers improved comfort and reduced radiation exposure without sacrificing performance.”
The Amigo system is designed to integrate easily into existing catheter labs for use in simple and complex procedures to diagnose and treat cardiac arrhythmias. It connects to the handle of specific electrophysiological catheters and lets the physician remotely operate the catheter with a controller. The system is intended to allow full operation of all catheter functions while reducing a physician’s radiation exposure during the procedure.
The Amigo system is compatible with Boston Scientific’s Blazer™ and Blazer™ Open-Irrigated radiofrequency (RF) ablation catheters and Chilli II® fluid cooled RF ablation catheter. The Blazer Open-Irrigated Catheter, launched in CE Mark countries in May 2011, is an advanced catheter that integrates Total Tip Cooling™ Design, which is intended to consistently cool the entire tip electrode during RF energy delivery.
“The Amigo system complements our leading line of EP catheters, offering electrophysiologists an intuitive solution for remote operation while retaining the full functionality of their preferred ablation catheter platforms,” said Michael Onuscheck, Executive Vice President and President of Boston Scientific EMEA. ”This agreement with Catheter Robotics is an important step in our continued focus on advancing cardiac ablation solutions for European physicians and their patients.”
Affecting more than 4.5 million Europeans, atrial fibrillation is an arrhythmia associated with a rapid rhythm in the upper chambers of the heart. Patients are most often treated with anti-arrhythmic drugs, which can often cause adverse side effects. Cardiac ablation with an RF ablation catheter is increasingly becoming an option for patients who cannot tolerate these medications.
In the U.S., the Blazer Open-Irrigated Catheter is an investigational device, limited by applicable law to investigational use only and not available for sale.
About Catheter Robotics, Inc.
Catheter Robotics, Inc. (CRI) is a medical device company focused on providing physicians comfort and safety while remaining committed to producing cost-effective, user friendly and technologically differentiated tools for use in percutaneous catheter procedures. For more information, please visit: www.catheterrobotics.com.
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans; our RFA catheters; the Amigo Remote Catheter System; product use, performance and compatibility; and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
CONTACT: Simonetta Balbi, PR and Corporate Communication EMEA, Balbis at bsci.com, Mobile : +39-3387936422
Tags: Austria, belgium, Boston Scientific Corporation, France, Germany, Luxembourg, Netherlands, November 15, Paris, Portugal, Spain, Switzerland